Divis Labs Q4 profit jumps 29% to Rs 502 crore on strong operating income, margin
In the year FY21, the COVID period, consolidated profit surged 44.2 percent to Rs 1,984.29 crore and revenue grew by 29.2 percent to Rs 6,969.4 crore compared to the previous year.
Divis Laboratories Ltd - 532488 - Corporate Action-Board approves Dividend
As per attachment DIVI'S LABORATORIES LTD. - 532488 - Intimation About Manufacturing Of Molnupiravir API
We hereby inform that Divi's Laboratories Limited (Divi's) is MSD's Authorized manufacturer for Molnupiravir API and we are allowed to supply this API to MSD's VL partners in India. This is for your information and records. Divis Laboratories Ltd - 532488 - Intimation Of Schedule Of Earnings Conference Call - Q4FY21
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings conference call - Q4 FY21 to be held on 29 May, 2021. Divis Laboratories Ltd - 532488 - Board Meeting Intimation for Declaration Of Audited Financial Results For Quarter And Year Ended 31 March, 2021 And Recommendation Of Dividend, If Any, For The Financial Year 2020-21.
DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2021 ,inter alia, to consider and approve Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, 29 May, 2021, inter-alia, to consider and approve standalone and consolidated audited financial results for the quarter and year ended 31 March, 2021 and to recommend dividend, if any, on equity shares for the financial year 2020-21. As intimated earlier, the Trading Window for dealing in securities of the Company has been closed from 01 April, 2021 till 48 hours after the declaration of financial results as per the Code of Conduct of the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is for your information and records. Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice to Shareholders - Transfer of Equity shares of the Company to the Investor Education and Protection Fund (IEPF) Authority Divis Laboratories Ltd - 532488 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayDIVI''S LABORATORIES LTD. 2CINL24110TG1990PLC011854 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NOTAPPLICABLE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: M. Satish Choudhury Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: L. Kishore Babu Designation: Chief Financial Officer EmailId: [email protected] Date: 17/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. DIVI'S LABORATORIES LTD. - 532488 - Certificate Pursuant To Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Half Year Ended March 31, 2021
Please find the enclosed certificate dated April 14, 2021 obtained from V. Bhaskara Rao & Associates, Practicing Company Secretaries for the half year ended March 31, 2021, pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.